A promising treatment for some children suffering from Thalassemia is?

UPUMS Nsg.Officer-2024

Pathology & Genetics

Easy

Appeared in: UPUMS Nsg.Officer-2024

Explanation

Bone marrow transplantation (BMT), or Hematopoietic Stem Cell Transplantation (HSCT), is the only established curative therapy for transfusion-dependent thalassemia.
The procedure works by replacing the patient's defective stem cells in the bone marrow with healthy stem cells from a compatible donor.
This allows the patient's body to begin producing normal, functional hemoglobin and red blood cells, correcting the underlying genetic defect.
Success rates are highest (over 80-90%) in younger patients who have a Human Leukocyte Antigen (HLA)-matched sibling donor and have not yet developed significant iron overload-related organ damage.

Option A: Chemotherapeutic agents are not a cure for thalassemia. While some agents like hydroxyurea can be used to increase levels of fetal hemoglobin (HbF) and reduce the need for transfusions in some patients, they do not fix the fundamental genetic problem.
Option B: Steroidal therapy has no role in the primary management of thalassemia, which is a genetic disorder of hemoglobin synthesis. Steroids do not influence hemoglobin production.
Option C: Radiation therapy, by itself, is not a treatment for thalassemia. It is a destructive process used to eliminate cells.

Clinical Relevance

Nursing practice connection: Knowing Curative treatment for Thalassemia helps nurses interpret findings accurately and avoid errors in routine assessment, medication administration, and patient teaching.
BMT is a high-risk, complex procedure. Nursing care is critical in managing the pre-transplant conditioning, administering immunosuppressive drugs to prevent rejection, and vigilantly monitoring for life-threatening complications like Graft-versus-Host Disease (GVHD) and infection.
Patient and family education is a key nursing responsibility, focusing on the importance of strict adherence to medication schedules, infection prevention measures (like hand hygiene and avoiding crowds), and the need for long-term follow-up care.
What if? If a patient does not have an HLA-matched sibling donor, the next options become more complex. These include transplants from matched unrelated donors (MUD) or haploidentical (half-matched) family donors, which carry higher risks. Newer options like gene therapy are also emerging as promising alternatives.

How to Approach the Question

First, identify the core of the question. It asks for a 'promising treatment' for thalassemia, which suggests a significant, potentially curative intervention, not just symptom management.
Recall the pathophysiology of thalassemia: it is a genetic disorder where the bone marrow produces defective hemoglobin. The root of the problem lies within the hematopoietic stem cells.
Evaluate the options based on this understanding. To cure a genetic defect in bone marrow cells, the most logical approach is to replace those cells entirely.
Analyze the distractors: Chemotherapy and steroids do not replace cells. Radiation destroys cells but doesn't provide new, healthy ones.
This line of reasoning leads directly to Bone Marrow Transplantation as the only option that replaces the faulty 'factory' (the bone marrow) with a new, functional one, thus offering a cure.

Concept Tested & Keywords

Q2i2Gw_AB6VB9ZZXUXq_8i

E6 Medicine Harrison 22e Part 1 p. 819-821

E6 Nelson Textbook of Pediatrics(2024) — Volume 2 p. 778-780

E6 Text Book Of Pediatric Nursing 3rd Panchali Pal — Part 2 (pp 239-476 of 713) p. 129-131